2. Cell Cycle/DNA Damage Epigenetics Apoptosis Stem Cell/Wnt
  3. HDAC Apoptosis Wnt β-catenin MDM-2/p53 c-Myc
  4. HIT211504993

HIT211504993 is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 0.070 μM. HIT211504993 suppresses cancer cell proliferation, cause G1 phase cell cycle arrest and induces apoptosis. HIT211504993 inhibits Myc-driven tumorigenesis via nucleocytoplasmic acetylation, p53 modulation, and Wnt/β-catenin signaling modulation. HIT211504993 inhibits tumor growth in a colon cancer xenograft mouse model. HIT211504993 can be used for the research of colon cancer.

For research use only. We do not sell to patients.

HIT211504993

HIT211504993 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

HIT211504993 Related Antibodies

Top Publications Citing Use of Products

View All HDAC Isoform Specific Products:

View All Isoforms
HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

View All Wnt Isoform Specific Products:

View All Isoforms
Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HIT211504993 is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 0.070 μM. HIT211504993 suppresses cancer cell proliferation, cause G1 phase cell cycle arrest and induces apoptosis. HIT211504993 inhibits Myc-driven tumorigenesis via nucleocytoplasmic acetylation, p53 modulation, and Wnt/β-catenin signaling modulation. HIT211504993 inhibits tumor growth in a colon cancer xenograft mouse model. HIT211504993 can be used for the research of colon cancer[1].

IC50 & Target[1]

HDAC6

0.07 μM (IC50)

In Vitro

HIT211504993 potently and selectively inhibits HDAC6, with an IC50 of 0.070 ± 0.002 μM, showing 89-fold higher potency against HDAC6 than HDAC2 and 486-fold higher potency than against HDAC4[1].
HIT211504993 ( 48 h) selectively inhibits the viability of colorectal cancer cells (HCT-8, HCT116) with IC50 of 12.483 and 18.840 μM and other tumor cell lines, with lower toxicity to normal NCM460 intestinal epithelial cells[1].
HIT211504993 (10-50 μM; 12-48 h) effectively enhances histone H3 and non-histone α-tubulin acetylation in HCT-8 and HCT116 colorectal cancer cells in both concentration- and time-dependent manners[1].
HIT211504993 (20 μM; 24 h) inhibits the long-term proliferative capacity of HCT-8 and HCT116 colorectal cancer cells, as measured by reduced colony formation[1].
HIT211504993 (20 μM; 12-48 h) induces G1 phase cell cycle arrest and downregulates Cyclin D expression in HCT-8 and HCT116 colorectal cancer cells, inhibiting cell proliferation[1].
HIT211504993 (20 μM; 12-48 h) induces time-dependent apoptosis in HCT-8 and HCT116 colorectal cancer cells via the intrinsic mitochondrial pathway, as shown by altered Bcl-2/Bax expression and increased Annexin V-positive cells[1].
HIT211504993 (60 μM; 6 h) directly binds to HDAC1 and HDAC2 in HCT-8 colorectal cancer cells, increasing their thermal stability[1].
HIT211504993 (20 μM; 4-24 h) modulates gene expression in HCT-8 colorectal cancer cells, downregulating MYC and Wnt/β-catenin pathway components while upregulating p53 and DUSP1, to suppress tumorigenesis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HIT211504993 Related Antibodies

Cell Viability Assay[1]

Cell Line: HCT-8, HCT116, NCM460, A2780, A549, MDA-MB-231, HepG2, HeLa, A375 cells
Concentration: 0.5-100 μM
Incubation Time: 48 h
Result: Exhibited an IC50 of 12.483 ± 0.92 μM in HCT-8 cells.
Exhibited an IC50 of 18.840 ± 0.88 μM in HCT116 cells.
Exhibited an IC50 of 46.043 ± 3.39 μM in NCM460 cells.
Exhibited an IC50 of 33.080 ± 3.98 μM in A2780 cells.
Exhibited an IC50 of 25.967 ± 5.45 μM in A549 cells.
Exhibited an IC50 of 10.782 ± 0.76 μM in MDA-MB-231 cells.
Exhibited an IC50 of 26.680 ± 1.75 μM in HepG2 cells.
Exhibited an IC50 of 56.557 ± 3.74 μM in HeLa cells.
Exhibited an IC50 of 20.983 ± 0.48 μM in A375 cells.

Western Blot Analysis[1]

Cell Line: HCT-8, HCT116 colorectal cancer cells
Concentration: 10, 20, 30, 40,50 μM
Incubation Time: 12, 24, 36, 48 h
Result: Increased acetyl-H3 and acetyl-α-tubulin levels in both cell lines, with the most substantial enhancement at 20 μM.
Induced time-dependent increases in acetyl-H3 and acetyl-α-tubulin levels in both cell lines when incubated for 12-48 h at 20 μM.

Cell Cycle Analysis[1]

Cell Line: HCT-8, HCT116 colorectal cancer cells
Concentration: 20 μM
Incubation Time: 12, 24, 36, 48 h
Result: Induced G1 phase cell cycle arrest in both HCT-8 and HCT116 cells.
Caused a significant decrease in Cyclin D protein expression in a time-dependent manner.

Apoptosis Analysis[1]

Cell Line: HCT-8, HCT116 colorectal cancer cells
Concentration: 20 μM
Incubation Time: 12, 24, 36, 48 h
Result: Induced apoptosis in a time-dependent manner, with progressive increases in apoptotic cell proportions over 12-48 h.
Downregulated anti-apoptotic Bcl-2 protein expression in both cell lines.
Upregulated pro-apoptotic Bax protein expression in both cell lines.

Real Time qPCR[1]

Cell Line: HCT-8 colorectal cancer cells
Concentration: 20 μM
Incubation Time: 4, 12, 24 h
Result: Altered the expression of 2692, 4788, and 5627 differentially expressed genes at 4, 12, and 24 h respectively, with enrichment in histone modification, cell cycle arrest, p53 signaling, and Wnt/β-catenin signaling pathways.
Induced time-dependent downregulation of MYC mRNA and protein expression.
Induced upregulation of DUSP1 and p53 mRNA and protein expression.
Downregulated mRNA levels of Wnt4, β-catenin, TCF4, and LEF1.
Reduced β-catenin protein expression in HCT-8 cells.
In Vivo

HIT211504993 (25-100 mg/kg; i.p.; daily; 15 days) suppresses HCT-8 colorectal cancer xenograft growth in a dose-dependent manner, achieving 77% tumor volume reduction at 50 mg/kg with favorable tolerability[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (4−6 weeks old, 16−20 g, subcutaneous xenograft via HCT-8 cell injection)[1]
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: I.p.; daily; 15 days
Result: Reduced tumor weight relative to vehicle control at 25 mg/kg.
Reduced tumor volume by 77% and tumor weight by 68% relative to vehicle control at 50 mg/kg.
Suppressed tumor growth to a greater extent than the 50 mg/kg dose at 100 mg/kg.
Caused no significant body weight changes or histological abnormalities in heart, liver, spleen, kidneys, or lungs across all treatment doses.
Molecular Weight

494.99

Formula

C23H27ClN2O6S
SMILES

O=C(C1CCC(CN(CC2=CC=CC(Cl)=C2)S(=O)(C3=CC=C4OCCOC4=C3)=O)CC1)NO
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

HIT211504993 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HIT211504993HIT 211504993HIT-211504993HDACApoptosisWntβ-cateninMDM-2/p53c-MycHistone deacetylasesBeta cateninMycp53colon cancer cellscolon cancerhistone deacetylase 6HCT-8Wnt/β-catenin signalingMyc-driven tumorigenesisHCT116HDAC6colon cancer xenograft mouse modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
HIT211504993
Cat. No.:
HY-181541
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.